The use of XALKORI® within ROS1+ advanced NSCLC
Dr Rohit Lal explains the use of Xalkori in ROS1+ advanced NSCLC through PROFILE 10011 study data before presenting real world data provided through a ROS1 clinical case study.
Specialising in the treatment of Thoracic cancers from the initial diagnosis through to controlling advanced cancers, Dr Rohit Lal provides top level care at Guys at St Thomas’ Hospital as a consultant Medical Oncologist. He has written numerous papers and continues to speak at national and international conferences.
1. Shaw, A. et al. Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): updated results from PROFILE 1001, Annals of Oncology, Volume 27, Issue suppl_6, 1 October 2016, 1206PD, https://doi.org/10.1093/annonc/mdw383.07
PP-XLK-GBR-0884. January 2019.